Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, has announced that its wholly-owned ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Granules strengthens ADHD portfolio with US FDA approval for lisdexamfetamine dimesylate capsules: Our Bureau, Bengaluru Thursday, January 30, 2025, 16:15 Hrs [IST] Granules India ...

Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Pharmaceuticals firm, Granules India Ltd on Thursday said its arm has received a final nod from the US health regulator for its generic version of ...

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

Granules India receives USFDA approval for its generic Lisdexamfetamine Dimesylate capsules, indicated for the treatment of ...

today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules.

At close: January 30 at 3:56:39 PM EST ...

The cannabidiol (CBD) world can feel huge and complicated, but products like CBD gummies make it more approachable for some folks. CBD gummies are easy to dose, portable, and discreet. They also ...